About rezolute inc - RZLT
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.
RZLT At a Glance
Rezolute, Inc.
275 Shoreline Drive
Redwood City, California 94065
| Phone | 1-650-206-4507 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -74,412,000.00 | |
| Sector | Health Technology | Employees | 71 | |
| Fiscal Year-end | 06 / 2026 | |||
| View SEC Filings |
RZLT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.393 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.163 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.009 |
RZLT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,048,056.338 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RZLT Liquidity
| Current Ratio | 14.367 |
| Quick Ratio | 14.367 |
| Cash Ratio | 14.092 |
RZLT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -48.284 |
| Return on Equity | -52.564 |
| Return on Total Capital | -45.445 |
| Return on Invested Capital | -52.078 |
RZLT Capital Structure
| Total Debt to Total Equity | 0.996 |
| Total Debt to Total Capital | 0.986 |
| Total Debt to Total Assets | 0.92 |
| Long-Term Debt to Equity | 0.606 |
| Long-Term Debt to Total Capital | 0.60 |